Adverse effects of Systemic Anti-Cancer Therapy (SACT): A study of patients and health care workers exposed to SACT
Authors:
- Sudath Shirley Pathmasiri WarnakulasuriyaSWSudath Shirley Pathmasiri Warnakulasuriya
- Meegoda Kankanange Dona Lalitha MeegodaMMMeegoda Kankanange Dona Lalitha Meegoda
- Sudheera Sammanthi JayasingheSJSudheera Sammanthi Jayasinghe
- Darshan Sri Indrajith Dammika De SilvaDSDarshan Sri Indrajith Dammika De Silva
- Rathnayaka Wasala Mohottalage Wasantha Kumara RathnayakaRRRathnayaka Wasala Mohottalage Wasantha Kumara Rathnayaka
- Nanayakkara Senarath Appuhamilage Samanthi Nisansala SenarathNSNanayakkara Senarath Appuhamilage Samanthi Nisansala Senarath
Preprint
- 19 November 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Despite the therapeutic effectiveness against cancer, Systemic Anti-Cancer Therapy (SACT) causes a wide range of adverse effects (AEs) among both patients and healthcare workers (HCWs). Methods A retrospective cohort and comparative study were conducted among randomly selected patients (n = 400) and HCWs (n = 360), including nurses, pharmacists, doctors, attendants, and cleaning staff. AEs among HCWs were compared with those in the control group (n = 420). A 50-item structured questionnaire was used to assess the prevalence, frequency, severity, and distress caused by AEs. Results A higher mean number of AEs was reported by patients (17.49 ± 2.87) and exposure group nurses (4.53 ± 2.58). Headaches, dizziness, drowsiness, nausea, skin and ocular irritation, and hair loss are more common among both patients and HCWs. The prevalence of common AEs was associated with the selected patient characteristics, and 75% of patients reported more than sixteen of the twenty common AEs. Among HCWs, nurses in the exposure group reported reproductive-related AEs, and the prevalence of AEs varied significantly across the occupational categories. Conclusions The findings of the study indicate that SACT is associated with a broad spectrum of AEs affecting both patients and HCWs. Therefore, effective strategies are required to manage SACT-associated AEs among patients and to strengthen occupational health and safety measures for HCWs exposed to SACT.Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- Classification of anticancer drugs: an update with FDA- and EMA-approved drugsCancer and Metastasis Reviews, 2024
- Principles of systemic anticancer therapy (SACT)Surgery (Oxford), 2024
- Influence of occupational exposure to antineoplastic agents on adverse pregnancy outcomes among nurses: A meta‐analysisNursing Open, 2023
- Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysiseClinicalMedicine, 2021
- Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapyApplied Materials Today, 2021
- Study on knowledge of chemotherapy's adverse effects and their self-care ability to manage - The cancer survivors impactClinical Epidemiology and Global Health, 2021
- An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their managementBest Practice & Research Clinical Gastroenterology, 2020
- USP General Chapter : Considerations for Oncology Nursing PracticeSeminars in Oncology Nursing, 2020
- Safety analysis of occupational exposure of healthcare workers to residual contaminations of cytotoxic drugs using FMECA security approachScience of The Total Environment, 2017
- Minimizing Occupational Exposure to Antineoplastic AgentsJournal of Infusion Nursing, 2016